<DOC>
	<DOCNO>NCT02605642</DOCNO>
	<brief_summary>To assess persistence Inflectra patient Rheumatoid Disease ( Rheumatoid arthritis [ RA ] , ankylose spondylitis [ AS ] , psoriatic arthritis [ PsA ] ) naive biologics switch stable Remicade Inflectra . The main objective study : - To evaluate real-life drug persistence RA , AS , PsA patient either initiate Inflectra™ first biologic , switch stable Remicade™ - To characterise patient population drug usage pattern RA , AS , PsA patient either initiate Inflectra™ first biologic , switch stable Remicade™ - To assess safety Inflectra™ RA , AS , PsA patient either initiate Inflectra™ first biologic , switch stable Remicade 2 year</brief_summary>
	<brief_title>Post-Marketing Use Of Inflectra ( Infliximab ) For Standard Of Care Treatment Of Rheumatoid Disease Who Are Naïve To Biologics Or Switched From Remicade™</brief_title>
	<detailed_description>The study conduct accord GCP guideline , data source validate . The source data consist medical record , physician questionnaire , patient questionnaire . Data study enter electronic data capture system . Questionnaires complete electronic tablet . The study one year enrollment period two year follow-up period . The study plan enroll patient throughout Canada Europe .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . Patients age ≥18 year old time enrollment 2 . Patients prescribed Inflectra Remicade treatment rheumatoid arthritis , ankylose spondylitis , psoriatic arthritis prescribe accord correspond summary product characteristic ( SmPC Product Monograph ) determine investigator 1 . Any report contraindication Inflectra accord SmPC Product Monograph 2 . Known hypersensitivity ( include severe , acute infusion reaction ) infliximab , excipients murine protein , time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Inflectra</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Observational</keyword>
	<keyword>Remicade</keyword>
</DOC>